FDA warns stem cell company over unapproved treatments
04-06-2019
mironovak / iStockphoto.com
Pharmaceutical distributor CanaRx Services has hit back at criticism from the US Food and Drug Administration over the Canadian company’s alleged supply of unapproved and misbranded drugs.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Food and Drug Administration, CanaRx services, pharmacies, drugs, warning letter, patient safety
